rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLCrpcardio-710Research ArticleTHERAPY GUIDELINESРЕКОМЕНДАЦИИ ПО ЛЕЧЕНИЮUSE OF N-3 POLYUNSATURATED FATTY ACIDS 90% (OMACOR) FOR THERAPY AND PREVENTION OF CARDIO-VASCULAR DISEASESПРИМЕНЕНИЕ N-3 ПОЛИНЕНАСЫЩЕННЫХ ЖИРНЫХ КИСЛОТ 90% (ОМАКОР) ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙРедакционнаястатья20111001201671103106Copyright © ., 20162016Редакционная с..Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/710
Заключение совещания экспертов 4 декабря 2010 года.
ReferencesSinclair H.M. The diet of Canadian Indians and Eskimos. Proc Nutr Soc 1953;12:69—82.Sinclair H.M. The diet of Canadian Indians and Eskimos. Proc Nutr Soc 1953;12:69—82.Lee J.H., O’Keefe J.H., Lavie C.J. et al. Omega-3 fatty acids for cardioprotection. Mayo Clin Proc 2008;83(3):324—332.Lee J.H., O’Keefe J.H., Lavie C.J. et al. Omega-3 fatty acids for cardioprotection. Mayo Clin Proc 2008;83(3):324—332.Harris W. Omega-3 fatty acids: the «Japanese» factor? J Am Coll Cardiol 2008;52(6):425—427.Harris W. Omega-3 fatty acids: the «Japanese» factor? J Am Coll Cardiol 2008;52(6):425—427.Tsaregorodtsev D.A., Gavva E.M., Sulimov V.A. Omega-3 Polyunsaturated Fatty Acids in the Treatment of Diseases of Cardiovascular System. Kardiologiia 2010;50(9):56-62. Russian (Царегородцев Д.А., Гавва Е.М., Сулимов В.А. Омега-3-полиненасыщенные жирные кислоты в лечении заболеваний сердечно-сосудистой системы. Кардиология 2010; 8: 56-62).Tsaregorodtsev D.A., Gavva E.M., Sulimov V.A. Omega-3 Polyunsaturated Fatty Acids in the Treatment of Diseases of Cardiovascular System. Kardiologiia 2010;50(9):56-62. Russian (Царегородцев Д.А., Гавва Е.М., Сулимов В.А. Омега-3-полиненасыщенные жирные кислоты в лечении заболеваний сердечно-сосудистой системы. Кардиология 2010; 8: 56-62).Fomin I.V., Belenkov Yu.N., Mareev V.Yu. et al. Prevalence of chronic heart failure in the European part of the Russian Federation: data from EPOCH-CHF. Serdechnaya Nedostatochnost 2006; 7 (3): 112-115. Russian (Фомин И.В., Беленков Ю.Н., Мареев В.Ю. и соавт. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации — данные ЭПОХА-ХСН. Сердечная Недостаточность 2006; 7 (3): 112-115).Fomin I.V., Belenkov Yu.N., Mareev V.Yu. et al. Prevalence of chronic heart failure in the European part of the Russian Federation: data from EPOCH-CHF. Serdechnaya Nedostatochnost 2006; 7 (3): 112-115. Russian (Фомин И.В., Беленков Ю.Н., Мареев В.Ю. и соавт. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации — данные ЭПОХА-ХСН. Сердечная Недостаточность 2006; 7 (3): 112-115).Ageev F.T., Danielyan M.O., Mareev V.Yu. et al. Patients with chronic heart failure in Russia's outpatient practice: the contingent features, diagnosis and treatment: study EPOCH-O-CHF. Serdechnaya Nedostatochnost 2004; 5 (1): 4-7. Russian (Агеев Ф.Т., Даниелян М.О., Мареев В.Ю. и соавт. Больные с хронической сердечной недостаточностью в российской амбулаторной практике: особенности контингента, диагностики и лечения: исследование ЭПОХА-О-ХСН. Сердечная Недостаточность 2004; 5 (1): 4-7).Ageev F.T., Danielyan M.O., Mareev V.Yu. et al. Patients with chronic heart failure in Russia's outpatient practice: the contingent features, diagnosis and treatment: study EPOCH-O-CHF. Serdechnaya Nedostatochnost 2004; 5 (1): 4-7. Russian (Агеев Ф.Т., Даниелян М.О., Мареев В.Ю. и соавт. Больные с хронической сердечной недостаточностью в российской амбулаторной практике: особенности контингента, диагностики и лечения: исследование ЭПОХА-О-ХСН. Сердечная Недостаточность 2004; 5 (1): 4-7).Swedberg K., Komajda M., Bohm M. et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376(9744): 875-885.Swedberg K., Komajda M., Bohm M. et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376(9744): 875-885.GISSI-HF investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372(9645): 1223-1130.GISSI-HF investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372(9645): 1223-1130.Gheorghiade M. Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. Heart Failure Society of America 2010 Scientific Meeting; September 15, 2010; San Diego, CA. Late-breaking clinical trials II.Gheorghiade M. Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. Heart Failure Society of America 2010 Scientific Meeting; September 15, 2010; San Diego, CA. Late-breaking clinical trials II.ACC/AHA/ESC 2006 Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 2006; 27(17): 2099-2140.ACC/AHA/ESC 2006 Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 2006; 27(17): 2099-2140.GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infraction: results of the GISSI-Prevenzione trial. Lancet 1999; 354(9177): 447–455.GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infraction: results of the GISSI-Prevenzione trial. Lancet 1999; 354(9177): 447–455.Raitt M., Connor W., Morris C. et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. JAMA 2005; 293(23): 2884-2891.Raitt M., Connor W., Morris C. et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. JAMA 2005; 293(23): 2884-2891.Leaf A., Albert C., Josephson M. et al., for the Fatty Acid Antiarrhythmia Trial Investigators. Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake. Circulation 2005; 112(18): 2762-2768.Leaf A., Albert C., Josephson M. et al., for the Fatty Acid Antiarrhythmia Trial Investigators. Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake. Circulation 2005; 112(18): 2762-2768.Brower I., Zock P., Camm A. et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial. JAMA 2006; 295(22): 2613-2619.Brower I., Zock P., Camm A. et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial. JAMA 2006; 295(22): 2613-2619.Calo L., Bianconi L., Colivicchi F. et al. N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol 2005; 45(10): 1723-1728.Calo L., Bianconi L., Colivicchi F. et al. N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol 2005; 45(10): 1723-1728.Panov A.V., Tatarskiy B.A., Gordeev M.L., Nilk R.Ya. Omega-3 polyunsaturated fatty acids in the prevention of atrial fibrillation after surgical myocardial revascularization. Rational Pharmacother Cardiol 2008; 3: 26-30. Russian (Панов А.В., Татарский Б.А., Гордеев М.Л., Нильк Р.Я. Омега-3-полиненасыщенные жирные кислоты в профилактике фибрилляции предсердий после хирургической реваскуляризации миокарда. Рациональная Фармакотерапия в Кардиологии 2008; 3: 26-30.Panov A.V., Tatarskiy B.A., Gordeev M.L., Nilk R.Ya. Omega-3 polyunsaturated fatty acids in the prevention of atrial fibrillation after surgical myocardial revascularization. Rational Pharmacother Cardiol 2008; 3: 26-30. Russian (Панов А.В., Татарский Б.А., Гордеев М.Л., Нильк Р.Я. Омега-3-полиненасыщенные жирные кислоты в профилактике фибрилляции предсердий после хирургической реваскуляризации миокарда. Рациональная Фармакотерапия в Кардиологии 2008; 3: 26-30.Yokoyama M., Origasa H., Matsuzaki M. et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007; 369(9567): 1090-1098.Yokoyama M., Origasa H., Matsuzaki M. et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007; 369(9567): 1090-1098.Mozaffarian D., Lemaitre R., Kuller L. et al. Cardiac benefits of fish consumption may depend on the type of fish meal consumed: the Cardiovascular Health Study. Circulation 2003; 107(10): 1372–1377.Mozaffarian D., Lemaitre R., Kuller L. et al. Cardiac benefits of fish consumption may depend on the type of fish meal consumed: the Cardiovascular Health Study. Circulation 2003; 107(10): 1372–1377.Kromhout D., Giltay E., Geleijnse J., for the Alpha Omega Trial Group. n–3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010; 363(21): 2015-2202.Kromhout D., Giltay E., Geleijnse J., for the Alpha Omega Trial Group. n–3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010; 363(21): 2015-2202.
The authors declare that there are no conflicts of interest present.